A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes



Status:Completed
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:May 2014
End Date:October 2015

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine

The main purpose of this study is to evaluate the use of the study drug known as dulaglutide
in participants with type II diabetes who are taking once-daily insulin glargine. The study
will last about 31 weeks for each participant.


Inclusion Criteria:

- Have type 2 diabetes (based on the World Health Organization's [WHO] diagnostic
criteria)

- Have been treated with basal insulin glargine once daily with or without metformin
for at least 3 months prior to screening

- Doses of once daily insulin glargine and metformin (if taken) must be stable during
the 3-month period prior to screening. Doses of metformin are considered stable if
all prescribed doses during this period are in the range between the minimum required
dose (≥1500 mg/day) and the maximum approved dose per the locally-approved label

- Have an HbA1c value ≥7.0% and ≤10.5% as assessed by the central laboratory at
screening

- Require further insulin glargine dose increase at week 3 per the treat-to-target
(TTT) algorithm based on the SMPG data collected during the prior week

- Have stable weight (±5%) ≥3 months prior to screening

- Have body mass index (BMI) ≤45 kilograms per square meter (kg/m^2) at screening

- Are able and willing to administer once weekly randomized therapy

- Are females of childbearing potential who must:

- Test negative for pregnancy at screening, based on a serum pregnancy test

- Agree to use a reliable method of birth control

- Not be breastfeeding

Exclusion Criteria:

- Have been treated with ANY other antihyperglycemia regimen, other than basal insulin
glargine once daily with or without metformin, within the 3 months prior to screening
or between screening and week 3

- Have a history of ≥1 episode of ketoacidosis or hyperosmolar state/coma

- Have a history of hypoglycemia unawareness within the 6 months prior to screening

- Have been treated with drugs that promote weight loss within the 3 months prior to
screening or between screening and week 3

- Are receiving chronic (>14 days) systemic glucocorticoid therapy or have received
such therapy within the 4 weeks prior to screening or between screening and week 3

- Have had any of the following cardiovascular conditions within the 2 months prior to
screening: acute myocardial infarction (MI), New York Heart Association (NYHA) Class
III or Class IV heart failure, or cerebrovascular accident (stroke)

- Have a known clinically significant gastric emptying abnormality or have undergone
gastric bypass surgery or restrictive bariatric surgery

- Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or
alanine aminotransferase (ALT) level >2.5 times the upper limit of the reference
range, as determined by the central laboratory

- Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were
diagnosed with any type of acute pancreatitis within the 3 months prior to screening

- Have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73
square meter (mL/min/m^2), calculated by the Chronic Kidney Disease-Epidemiology
(CKD-EPI) equation, as determined by the central laboratory; for participants on
metformin, have renal disease or renal dysfunction (for example, a serum creatinine
≥1.5 mg/deciliter [dL] [male] or ≥1.4 mg/dL [female] or eGFR [CKD-EPI] <60
mL/min/1.73 m^2)

- Have evidence of a significant, uncontrolled endocrine abnormality

- Have any self or family history of type 2A or type 2B multiple endocrine neoplasia
(MEN 2A or 2B) in the absence of known C-cell hyperplasia

- Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia,
or carcinoma (including sporadic, familial, or part of MEN 2A or 2B syndrome)

- Have serum calcitonin ≥20 picograms/mL, as determined by the central laboratory

- Have evidence of a significant, active autoimmune abnormality

- Have any other condition not listed in this section that is a contraindication for
use of insulin glargine, or, for participants using metformin, have a condition that
is a contraindication for the use of metformin and would require metformin
discontinuation per label

- Have a history of transplanted organ

- Have a history of active or untreated malignancy, or are in remission from a
clinically significant malignancy during the 5 years prior to screening

- Have a history of any other condition which, in the opinion of the investigator, may
preclude the participants from following and completing the protocol

- Have any hematologic condition that may interfere with HbA1c measurement (eg,
hemolytic anemias, sickle-cell disease)
We found this trial at
14
sites
Renton, Washington 98057
?
mi
from
Renton, WA
Click here to add this to my saved trials
Arlington Heights, Illinois 60005
?
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
?
mi
from
Beroun,
Click here to add this to my saved trials
Fresno, California 93720
?
mi
from
Fresno, CA
Click here to add this to my saved trials
Greensboro, North Carolina 27401
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
?
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Knoxville, Tennessee 37912
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Las Vegas, Nevada 89119
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lexington, Kentucky 40503
?
mi
from
Lexington, KY
Click here to add this to my saved trials
San Mateo, California 94401
?
mi
from
San Mateo, CA
Click here to add this to my saved trials
Seattle, Washington 98122
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Toms River, New Jersey
?
mi
from
Toms River, NJ
Click here to add this to my saved trials
Topeka, Kansas 66606
?
mi
from
Topeka, KS
Click here to add this to my saved trials
Tustin, California 92780
?
mi
from
Tustin, CA
Click here to add this to my saved trials